Investigational drug · Phase 3
Iptilimumab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Brain Tumor, Non Small Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "Iptilimumab"
First trial start
2022
Aug 12, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Iptilimumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Brain Tumor
- Non Small Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Iptilimumab" as an intervention, largest first.
- Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain MetsPivotal-lookingRecruiting
InSightecIndustry
NCT05317858 · 96 participants (planned) · Start Aug 12, 2022 · Primary completion Jun 1, 2031
Drug: Pembrolizumab; Atezolizumab and 3 more · For: Brain Tumor; Non Small Cell Lung Cancer
Sites: Phoenix, Arizona; Newport Beach, California; Fort Lauderdale, Florida · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Brain Tumor
- APL-101Phase 21 trial
Apollomics Inc. · Solid Tumors, Advanced Cancer, Renal Cancer
- BCB-276Phase 21 trial
BrainChild Bio, Inc · Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor
- RVP-001Mn-PyC3A, mangaveratePhase 21 trial
Reveal Pharmaceuticals Inc. · Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms
- TNG456Phase 21 trial
Tango Therapeutics, Inc. · Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.